Get started
Author

Karen P. Balcazar

Observed name: Karen Balcazar
Observed institution: Xencor (United States)
ORCID: 0009-0000-7597-5855
Observed ORCID: 0009-0000-7597-5855
OpenAlex ID: A5107526008
A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2024 · Gregory L. Moore, Veronica G. Zeng, et al. · Molecular Cancer Therapeutics · 21
PDF
Tu1468 DISCOVERY AND CHARACTERIZATION OF XMAB412: A NOVEL, HIGH-AFFINITY, ANTI-TL1A X ANTI-IL23 NATIVE-LIKE BISPECIFIC ANTIBODY WITH EXTENDED HALF-LIFE FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
2026 · Matthew S. Faber, Kendra N. Avery, et al. · Gastroenterology · 1
1074 A CD2 co-stimulatory platform enhances T cell engager potency across multiple tumor targets without non-specific T cell activation
2026 · Tian Zhang, Alex Nisthal, et al. · Journal for ImmunoTherapy of Cancer
PDF
CD2 x IL2RG bispecific antibodies synergistically modulate lymphocyte activation, resulting in suppression of inflammation and prevention of GVHD 2258985
2026 · Ke Liu, Michael Cadell, et al. · The Journal of Immunology
PDF
Tu1468 DISCOVERY AND CHARACTERIZATION OF XMAB412: A NOVEL, HIGH-AFFINITY, ANTI-TL1A X ANTI-IL23 NATIVE-LIKE BISPECIFIC ANTIBODY WITH EXTENDED HALF-LIFE FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
2026 · Matthew S. Faber, Kendra N. Avery, et al. · Gastrointestinal Endoscopy
Figure 3 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Figure 4 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Figure 5 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Figure 1 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Figure 6 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Supplementary Figure S1 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Supplementary Figure S2 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Data from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Figure 2 from A B7-H3–Targeted CD28 Bispecific Antibody Enhances the Activity of Anti–PD-1 and CD3 T-cell Engager Immunotherapies
2025 · Gregory L. Moore, Veronica G. Zeng, et al.
Works count: 14
Citation count: 22
H-index: 1
I10-index: 1
Year
Topic
Type